|
Study
|
Dose
|
DLTs
|
Number of patients evaluable for DLT
|
Proportion of patients who experienced a DLT
|
P (DLT) for true dose toxicity curve
|
|---|
|
AZD3514
|
250 mg QD
|
0
|
6
|
0%
|
0%
|
|
500 mg QD
|
0
|
6
|
0%
|
0%
|
|
1000 mg QD
|
1
|
6
|
17%
|
17%
|
|
1000 mg BID
|
3
|
6
|
50%
|
50%
|
|
2000 mg BID
|
4
|
4
|
100%
|
100%
|
|
AZD1208
|
120 mg QD
|
0
|
3
|
0%
|
0%
|
|
240 mg QD
|
0
|
3
|
0%
|
0%
|
|
480 mg QD
|
0
|
3
|
0%
|
0%
|
|
700 mg QD
|
1
|
4
|
25%
|
25%
|
|
900 mg QD
|
2
|
3
|
67%
|
67%
|
|
AZD1480
|
15 mg BIDa
|
0
|
4
|
0%
|
0%
|
|
20 mg BID
|
1
|
5
|
20%
|
20%
|
|
30 mg BID
|
1
|
5
|
20%
|
20%
|
|
35 mg BID
|
2
|
3
|
67%
|
67%
|
|
45 mg BID
|
0
|
2
|
0%
|
67%
|
|
AZD4877
|
2 mg twice weekly
|
0
|
3
|
0%
|
0%
|
|
4 mg twice weekly
|
0
|
3
|
0%
|
0%
|
|
7 mg twice weekly
|
0
|
3
|
0%
|
0%
|
|
11 mg twice weekly
|
0
|
6
|
0%
|
0%
|
|
15 mg twice weekly
|
2
|
2
|
100%
|
100%
|
- aTaken from another study on AZD1480
- BID: twice daily; QD: once daily
